Company research
Quantum-Si Inc
CIK 1816431Updated Sep 24, 2026
Securities
Name history
HighCape Capital Acquisition Corp. · through Jun 10, 2021
CAPA price & chart
Historical security
This listing closed Jun 10, 2021. Live provider charts are shown only for current listings.
About the company
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
In the news
ディファイアンスETFs、米国上場初のコンデンサ＆MLCC ETFであるCAPAをローンチ ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 245,607,000Source | 247,871,000Source | 298,250,000Source | 391,485,000Source |
| Property, Plant and Equipment, NetUSD | 13,194,000Source | 15,993,000Source | 16,275,000Source | 16,849,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,639,000Source | 49,241,000Source | 133,860,000Source | 84,319,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 561,000Source | 1,333,000Source | 368,000Source | — |
| Inventory, NetUSD | 3,197,000Source | 4,067,000Source | 3,945,000Source | — |
| Assets, CurrentUSD | 175,860,000Source | 218,009,000Source | 266,310,000Source | 358,182,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,554,000Source | 3,006,000Source | 4,261,000Source | 6,873,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,464,000Source | 13,061,000Source | 14,438,000Source | 15,757,000Source |
| Other Assets, NoncurrentUSD | 234,000Source | 808,000Source | 695,000Source | 697,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 25,381,000Source | 32,451,000Source | 26,631,000Source | 32,779,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 918,190,000Source | 811,998,000Source | 767,239,000Source | 758,366,000Source |
| Retained Earnings (Accumulated Deficit)USD | -697,980,000Source | -596,641,000Source | -495,634,000Source | -399,674,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,000Source | 45,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 220,226,000Source | 215,420,000Source | 271,619,000Source | 358,706,000Source |
| Liabilities and EquityUSD | 245,607,000Source | 247,871,000Source | 298,250,000Source | 391,485,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 23,025,000Source | 18,187,000Source | 11,609,000Source | 15,706,000Source |
| Operating Lease, Liability, CurrentUSD | 1,844,000Source | 3,698,000Source | 1,566,000Source | 1,369,000Source |
| Accounts Payable, CurrentUSD | 1,623,000Source | 1,931,000Source | 1,766,000Source | 3,903,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,322,000Source | 9,250,000Source | 13,737,000Source | 16,077,000Source |
| Other Liabilities, NoncurrentUSD | 34,000Source | 19,000Source | 11,000Source | 0Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 215,800,000Source | 209,600,000Source | — | — |
| Deferred Revenue, CurrentUSD | 133,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,454,000Source | 4,600,000Source | 4,156,000Source | 2,584,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,773,000Source | 8,887,000Source | 8,516,000Source | 11,206,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -626,000Source | 1,089,000Source | 368,000Source | — |
| Increase (Decrease) in InventoriesUSD | 2,006,000Source | -4,342,000Source | 3,096,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -338,000Source | 390,000Source | -1,220,000Source | 721,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -94,717,000Source | -87,795,000Source | -94,036,000Source | -90,560,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -28,320,000Source | -32,675,000Source | 143,428,000Source | 137,185,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,517,000Source | 4,583,000Source | 4,510,000Source | 10,741,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 95,423,000Source | 35,876,000Source | 149,000Source | 1,909,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -27,602,000Source | -84,619,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 21,639,000Source | 49,241,000Source | 133,860,000Source | 84,319,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 24,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 12,000Source | -25,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,773,000Source | 8,887,000Source | 8,516,000Source | 11,206,000Source |
| Amortization of Intangible AssetsUSD | 0Source | 600,000Source | 200,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 215,800,000Source | 209,600,000Source | — | — |
| Debt Securities, Trading, Gain (Loss)USD | — | — | 5,587,000Source | -20,603,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -31,000Source | -425,000Source | -136,000Source | -91,000Source |
| Gain (Loss) on Termination of LeaseUSD | -13,577,000Source | — | — | — |
| GoodwillUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | 9,483,000Source |
| Income Tax Expense (Benefit)USD | 58,000Source | 56,000Source | 0Source | 0Source |
| Inventory Write-downUSD | 2,290,000Source | -3,229,000Source | 3,400,000Source | — |
| Investment Income, InterestUSD | 8,964,000Source | 9,638,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -101,339,000Source | -101,007,000Source | -95,960,000Source | -132,442,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -101,339,000Source | -101,007,000Source | -95,960,000Source | -132,442,000Source |
| Operating ExpensesUSD | 117,252,000Source | 110,176,000Source | 111,659,000Source | 123,841,000Source |
| Other Nonoperating Income (Expense)USD | 955,000Source | -19,000Source | 366,000Source | -20,145,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 34,789,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 1,912,000Source | 1,072,000Source | 357,000Source | 2,757,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,436,000Source | 3,058,000Source | 1,082,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 44,754,000Source | 50,535,000Source | 44,634,000Source | 42,296,000Source |
| Operating Income (Loss)USD | -116,099,000Source | -108,576,000Source | -111,171,000Source | -123,841,000Source |
| Other Nonoperating Income (Expense)USD | 955,000Source | -19,000Source | 366,000Source | -20,145,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -101,281,000Source | -100,951,000Source | -95,960,000Source | -132,442,000Source |
| Income Tax Expense (Benefit)USD | 58,000Source | 56,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -101,339,000Source | -101,007,000Source | -95,960,000Source | -132,442,000Source |
| Earnings Per Share, BasicUSD per share | -0.51Source | -0.71Source | -0.68Source | -0.95Source |
| Earnings Per Share, DilutedUSD per share | -0.51Source | -0.71Source | -0.68Source | -0.95Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 197,765,000Source | 143,196,000Source | 141,300,000Source | 139,255,131Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 197,765,000Source | 143,196,000Source | 141,300,000Source | 139,255,131Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 0Source | 600,000Source | 200,000Source | — |
| Current Income Tax Expense (Benefit)USD | 58,000Source | 56,000Source | 0Source | — |
| Debt Securities, Trading, Gain (Loss)USD | — | — | 5,587,000Source | -20,603,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,500,000Source | 4,600,000Source | 4,200,000Source | — |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | 9,483,000Source |
| Gross ProfitUSD | 1,153,000Source | 1,600,000Source | 488,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -103,891,000Source | -101,108,000Source | -95,977,000Source | — |
| Interest ExpenseUSD | — | — | — | 0Source |
| Interest Income (Expense), NetUSD | — | — | 0Source | — |
| Investment Income, InterestUSD | 8,964,000Source | 9,638,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -101,339,000Source | -101,007,000Source | -95,960,000Source | -132,442,000Source |
| Operating ExpensesUSD | 117,252,000Source | 110,176,000Source | 111,659,000Source | 123,841,000Source |
| Research and Development ExpenseUSD | 53,759,000Source | 59,641,000Source | 67,025,000Source | 72,062,000Source |
Filing attachments
qsi8132026ex991.htm · 8-K · 2026-08-13
EX-99.1 2 qsi8132026ex991.htm EX-99.1 Document Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD, Conn. -- (GLOBE NEWSWIRE) -- August 13, 2026 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the …
Read attachment ↗qsi8132026ex992.htm · 8-K · 2026-08-13
EX-99.2 3 qsi8132026ex992.htm EX-99.2 Document Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated August 13, 2026 announcing results for the three and six months ended June 30, 2026, that accompany a conferenc…
Read attachment ↗qsi572026ex991.htm · 8-K · 2026-05-07
EX-99.1 2 qsi572026ex991.htm EX-99.1 Document Exhibit 99.1 Quantum-Si Reports First Quarter 2026 Financial Results and Highlights ProteusTM Development Milestones Successful sequencing on integrated Proteus instruments and continued progress toward amino acid coverage and overall launch capabilities BRANFORD, Conn. -- (BUSINESS WIRE) -- May 7, 2026 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis …
Read attachment ↗qsi572026ex992.htm · 8-K · 2026-05-07
EX-99.2 3 qsi572026ex992.htm EX-99.2 Document Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated May 7, 2026 announcing results for the three months ended March 31, 2026, that accompany a conference call to be…
Read attachment ↗qsi-332026xex991.htm · 8-K · 2026-03-03
EX-99.1 2 qsi-332026xex991.htm EX-99.1 Document Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results Releases List Price of ProteusTM Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch BRANFORD, Conn. -- (BUSINESS WIRE) -- March 3, 2026 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced …
Read attachment ↗qsi-332026xex992.htm · 8-K · 2026-03-03
EX-99.2 3 qsi-332026xex992.htm EX-99.2 Document Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated March 3, 2026 announcing results for the fourth quarter and full year ended December 31, 2025, that accompany …
Read attachment ↗